The Ischemic Heart Disease (IHD) Drugs Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Ischemic Heart Disease (IHD) Drugs Market?
The market size of ischemic heart disease (IHD) drugs has been witnessing robust growth in the past few years. The market is projected to expand from $6.36 billion in 2024 to $6.71 billion in 2025, registering a compound annual growth rate (CAGR) of 5.6%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Ischemic Heart Disease (IHD) Drugs Industry?
The Ischemic Heart Disease (IHD) Drugs Global Market is forecasted to reach $7.86 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.0%.
Download Your Free Sample of the 2025 Ischemic Heart Disease (IHD) Drugs Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Ischemic Heart Disease (IHD) Drugs Market?
The key drivers in the ischemic heart disease (ihd) drugs market are:
• Aging population trends leading to higher demand for IHD drugs
• Emphasis on personalized medicine approaches for IHD treatment
• Increased focus on cardiovascular prevention on a global scale
• Growth fueled by global health policies, initiatives, and international research collaborations
Global Market Segmentation: Identifying Major Ischemic Heart Disease (IHD) Drugs Industry Segments
The ischemic heart disease (IHD) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Pre-order the 2025 Ischemic Heart Disease (IHD) Drugs Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Ischemic Heart Disease (IHD) Drugs Market?
The key trends in the ischemic heart disease (ihd) drugs market are:
• The shift towards precision medicine approaches is shaping the future of the IHD drugs market.
• There is an increased focus on novel anti-atherogenic agents in the industry.
• Advancements in lipid-lowering therapies are a key emerging trend.
• The market is influenced by the development of antithrombotic and antiplatelet drugs.
Who Are the Top Competitors & Leading Players in the Ischemic Heart Disease (IHD) Drugs Market?
Major companies in the ischemic heart disease (ihd) drugs market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz Inc.
• Sun Pharmaceutical Industries Limited
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Lupin Limited
• Recordati S.p.A.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Alembic Pharmaceuticals Ltd.
• Eagle Pharmaceuticals Inc.
• Accord Healthcare Limited
• Macleods Pharmaceuticals Ltd.
• WG Critical Care LLC
• Novitium Pharma LLC
Regional Dominance: Which Area Leads the Global Ischemic Heart Disease (IHD) Drugs Market?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024
